Search

Your search keyword '"Florenzano, Maria Teresa"' showing total 4 results
Start Over Author "Florenzano, Maria Teresa"
4 results on '"Florenzano, Maria Teresa"'

1. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2023
Full Text
View/download PDF

2. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2023
Full Text
View/download PDF

3. Identifying and Managing CAR T-Cell–Mediated Toxicities: on behalf of an Italian CAR-T Multidisciplinary Team

Author

Martino, Massimo, primary, Macheda, Sebastiano, additional, Aguglia, Umberto, additional, Arcudi, Luciano, additional, Pucci, Giulia, additional, Martino, Bruno, additional, Altomonte, Maria, additional, Rossetti, Antonio Maria, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Imbalzano, Lucrezia, additional, Stelitano, Caterina, additional, Alati, Caterina, additional, Germano’, Jessyca, additional, Labate, Demetrio, additional, Amalfi, Vincenzo, additional, Florenzano, Maria Teresa, additional, Morabito, Antonella, additional, Borzumati, Vittoria, additional, Dattola, Vincenzo, additional, Gattuso, Caterina, additional, Moschella, Antonio, additional, Quattrone, Domenico, additional, Curmaci, Francesco, additional, Franzutti, Claudio, additional, Scappatura, Giuseppe, additional, Rao, Carmelo Massimiliano, additional, Loddo, Viviana, additional, Pontari, Antonella, additional, Pellicano’, Maria, additional, Surace, Rosangela, additional, Sanguedolce, Cristina, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Irrera, Giuseppe, additional, Console, Giuseppe, additional, Moscato, Tiziana, additional, Loteta, Barbara, additional, Canale, Filippo Antonio, additional, Trimarchi, Alfonso, additional, Monteleone, Renza, additional, Said, Al Sayyad, additional, Cirrone, Frank, additional, and Bruno, Benedetto, additional

Published
2021
Full Text
View/download PDF

4. Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team

Author

Martino, Massimo, Macheda, Sebastiano, Aguglia, Umberto, Arcudi, Luciano, Pucci, Giulia, Martino, Bruno, Altomonte, Maria, Rossetti, Antonio Maria, Cusumano, Giuseppa, Russo, Letteria, Imbalzano, Lucrezia, Stelitano, Caterina, Alati, Caterina, Germano’, Jessyca, Labate, Demetrio, Amalfi, Vincenzo, Florenzano, Maria Teresa, Morabito, Antonella, Borzumati, Vittoria, Dattola, Vincenzo, Gattuso, Caterina, Moschella, Antonio, Quattrone, Domenico, Curmaci, Francesco, Franzutti, Claudio, Scappatura, Giuseppe, Rao, Carmelo Massimiliano, Loddo, Viviana, Pontari, Antonella, Pellicano’, Maria, Surace, Rosangela, Sanguedolce, Cristina, Naso, Virginia, Ferreri, Anna, Irrera, Giuseppe, Console, Giuseppe, Moscato, Tiziana, Loteta, Barbara, Canale, Filippo Antonio, Trimarchi, Alfonso, Monteleone, Renza, Al Sayyad, Said, Cirrone, Frank, and Bruno, Benedetto

Abstract

ABSTRACTIntroductionChimeric antigen receptor (CAR)-T-cell therapy is a new treatment for patients with hematologic malignancies in which other therapies have failed.Areas coveredThe review provides an overview for recognizing and managing the most acute toxicities related to CAR-T cells.Expert opinionThe development of immune-mediated toxicities is a common challenge of CAR-T therapy. The mechanism that determines this toxicity is still unclear, although an unfavorable tumor microenvironment and a pro-inflammatory state put patients at risk. The monitoring, diagnosis, and treatment of post-CAR-T toxicities must be determined and based on international guidelines and internal clinical practice. It is urgent to identify biomarkers that can identify patients at greater risk of developing complications. The adoption of consistent grading criteria is necessary to improve toxicity management strategies continually. The first-line therapy consists of supportive care and treatment with tocilizumab or corticosteroids. An early start of cytokine blockade therapies could mitigate toxicity. The plan will include cytokine release prophylaxis, a risk-adapted treatment, prevention of on-target/off-tumor effect, and a switch on/off CAR-T approach.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results